These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Response to low-dose desmopressin by a subcutaneous route in children with type 1 von Willebrand disease.
    Author: Akin M.
    Journal: Hematology; 2013 Mar; 18(2):115-8. PubMed ID: 23321055.
    Abstract:
    OBJECTIVE: The primary objective of this study was to determine responses to low-dose desmopressin (DDAVP) by a subcutaneous route in children with type 1 VWD. METHODS: This study analyzed responses to low doses of DDAVP administered by a subcutaneous route to 14 children between the ages of 3 and 16 with type 1 VWD and a personal and familial history of bleeding. At 0 (baseline) and 1 hour (initial response) after the subcutaneous injection of DDAVP, the vital signs were assessed and blood samples were obtained for VWD panel determinations (VWF:Ag, VWF:RCo, FVIII:C levels, and Col/Epi, Col/ADP). At 4 hours (sustained response), only Col/Epi and Col/ADP were assessed. RESULTS: The DDAVP mean (min-max range, μg/kg) based on the patient's weight was 0.15 (0.12-0.18). Laboratory values mean (min-max range in U/dl) baseline for VWF:RCo, VWF:Ag, and FVIII:C were 28 (20-36), 34 (25-42), and 40 (29-48), respectively. After a subcutaneous administration, the laboratory values mean (min-max range in U/dl(-1)) achieved for 1 hour for VWF:RCo, VWF:Ag, and FVIII:C were 109 (72-144), 132 (88-166), and 151 (96-198), respectively. PFA 100(®) CT (Col/Epi <134 seconds and Col/ADP <110 seconds) returned to normal values at 1 and 4 hours after a subcutaneous administration. CONCLUSION: Subcutaneous low-dose DDAVP therapy is at least effective as 0.3 µg/kg intravenous therapy for children with type 1 VWD. This study shows that a wider use of DDAVP should be promoted, especially in developing countries.
    [Abstract] [Full Text] [Related] [New Search]